Rankings
▼
Calendar
KMDA Q3 2025 Earnings — Kamada Ltd. Revenue & Financial Results | Market Cap Arena
KMDA
Kamada Ltd.
$520M
Q3 2025 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$47M
+12.6% YoY
Gross Profit
$20M
42.0% margin
Operating Income
$8M
16.6% margin
Net Income
$5M
11.3% margin
EPS (Diluted)
$0.09
QoQ Revenue Growth
+5.0%
Cash Flow
Operating Cash Flow
$10M
Free Cash Flow
$7M
Stock-Based Comp.
$117,000
Balance Sheet
Total Assets
$377M
Total Liabilities
$112M
Stockholders' Equity
$265M
Cash & Equivalents
$72M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$47M
$42M
+12.6%
Gross Profit
$20M
$17M
+14.7%
Operating Income
$8M
$5M
+47.6%
Net Income
$5M
$4M
+37.1%
← Q2 2025
All Quarters